Fig. 4From: Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I studyAnti-Factor Xa activity versus plasma concentrations; rivaroxaban 10 mg and 20 mg-equivalent doses for all age groups (n = 59) with (a) rivaroxaban tablet and (b) rivaroxaban suspension. Anti-Factor Xa activity within the 24 h after administration of rivaroxaban; eq., equivalentBack to article page